Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 6/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435013 | 0.91 | HSD11B1 (0.68) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL1807409 | 0.86 | HSD11B1 (0.60) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL436643 | 0.85 | DPP4 (0.52) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL872447 | 0.84 | HSD11B1 (0.50) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL433244 | 0.83 | SLC6A3 (0.59) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL8485828 | 0.83 | DPP4 (0.53) | HSD11B1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL4245329 | 0.81 | HSD11B1 (0.97) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL1807144 | 0.80 | HSD11B1 (0.54) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 | |
| SCHEMBL18440285 | 0.80 | EPHX2 (0.52) | HSD11B1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL627571 | 0.78 | HSD11B1 (0.90) | HSD11B1SLC6A3CACNA1GSLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| CN-102686571-B | tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2015-11-25 | — | — | CN | disclosed |
| EP-2595969-B1 | Substituted 3-phenyl-1,2,4-oxadiazole compounds | BRISTOL MYERS SQUIBB CO (US) | 2015-04-22 | — | — | EP | disclosed |
| CN-103124727-B | Substituted 3-phenyl-1,2,4-oxadiazole compounds | BRISTOL MYERS SQUIBB CO | 2015-03-25 | — | — | CN | disclosed |
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
| EP-2595969-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2013-05-29 | — | — | EP | disclosed |
| CN-103124727-A | Substituted 3-phenyl-1,2,4-oxadiazole compounds | BRISTOL MYERS SQUIBB CO | 2013-05-29 | — | — | CN | disclosed |
| CN-102686571-A | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO | 2012-09-19 | — | — | CN | disclosed |
| EP-2493866-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| WO-2012012477-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2011059784-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059784-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, TBXA2R | HSD11B1 782/4885SLC6A3 3263/4885CACNA1G 705/4885 |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | HSD11B1 983/4885SLC6A3 2766/4885CACNA1G 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.